Who are Adaptive Biotechnologies's decision-makers?
Adaptive Biotechnologies's leadership team is anchored by Chad Robins. Enterprise purchases usually require sponsorship from the business owner plus finance, procurement, legal, security, compliance, and IT or data leaders.
- CEO
- Chad Robins
- CFO/key exec
- Tycho Peterson
- Founded
- 2009
- Employees
- 750+
- HQ
- Seattle, WA
- Notable
- Nasdaq: ADPT
- Chad RobinsCo-founder and Chief Executive OfficerCEO since foundingLeads immune medicine platform strategy.
- Tycho PetersonChief Financial OfficerCFOOwns finance, investor relations, and capital allocation.
- Harlan RobinsCo-founder and Chief Scientific OfficerCo-founderLeads scientific platform and immune-repertoire expertise.
- Nitin SoodChief Commercial OfficerCommercial leaderLeads MRD commercialization and market access.
Who leads Adaptive Biotechnologies?
Chad Robins serves as Co-founder and Chief Executive Officer; Tycho Peterson serves as Chief Financial Officer; Harlan Robins serves as Co-founder and Chief Scientific Officer; Nitin Sood serves as Chief Commercial Officer. The team combines category, finance, commercial, clinical, technical, and operations ownership.
For account mapping, treat the named leaders as executive context rather than the only buying path. Most projects will start with a functional sponsor and move upward only after a clear business case exists.
Who actually makes buying decisions at Adaptive Biotechnologies?
Budget ownership depends on the project: commercial leaders own revenue tools, clinical and product leaders own workflow and evidence needs, technology leaders own platform and security fit, and finance or procurement controls approval thresholds.
Because Adaptive Biotechnologies operates in healthcare or life sciences, legal, privacy, compliance, quality, and information-security review can be as important as the economic buyer.
How is Adaptive Biotechnologies organized as it scales?
Adaptive Biotechnologies should be approached as a public-company operating organization with business units, functional teams, and governance layers. The company has 750+ employees and operates from Seattle, WA with additional offices or distributed teams.
Good account plans identify the operational metric at stake, the system of record involved, the compliance requirement, the implementation owner, and the executive sponsor before asking for a broad enterprise commitment.
As of June 2026.Sources:Adaptive websiteAdaptive full-year 2025 results
Adaptive Biotechnologies — frequently asked questions
